Martin Black, MD; Marion Peters, MD
For two decades, therapy for viral hepatitis has included alpha-interferon, but only this year was the drug licensed for treatment of chronic non-A, non-B hepatitis. The licensing of the drug for use in patients with non-A, non-B hepatitis, rather than only in those with a specific diagnosis of hepatitis C (HCV), reflects both state-of-the-art knowledge of HCV testing with the commercially available test for antibodies to HCV (anti-HCV) (70% to 80% positive in "high-risk" populations; that is, those with risk factors for non-A, non-B hepatitis infection) as well as the possibility that there are "non-A, non-B, non-C" viruses yet to
Learn more about subscription options.
Register Now for a free account.
Black M, Peters M. Alpha-Interferon Treatment of Chronic Hepatitis C: Need for
Accurate Diagnosis in Selecting Patients. Ann Intern Med. 1992;116:86–88. doi: 10.7326/0003-4819-116-1-86
Download citation file:
Published: Ann Intern Med. 1992;116(1):86-88.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only